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Abstract
Background: Prostate cancer (CaP) is the second leading cause of cancer death in American men. Androgen deprivation
therapy is initially effective in CaP treatment, but CaP recurs despite castrate levels of circulating androgen. Continued
expression of the androgen receptor (AR) and its ligands has been linked to castration-recurrent CaP growth.
Principal Finding: In this report, the ligand-dependent dominant-negative ARD142–337 (ARDTR) was expressed in
castration-recurrent CWR-R1 cell and tumor models to elucidate the role of AR signaling. Expression of ARDTR decreased
CWR-R1 tumor growth in the presence and absence of exogenous testosterone (T) and improved survival in the presence of
exogenous T. There was evidence for negative selection of ARDTR transgene in T-treated mice. Mass spectrometry revealed
castration-recurrent CaP dihydrotestosterone (DHT) levels sufficient to activate AR and ARDTR. In the absence of exogenous
testosterone, CWR-R1-ARDTR and control cells exhibited altered androgen profiles that implicated epithelial CaP cells as a
source of intratumoral AR ligands.
Conclusion: The study provides in vivo evidence that activation of AR signaling by intratumoral AR ligands is required for
castration-recurrent CaP growth and that epithelial CaP cells produce sufficient active androgens for CaP recurrence during
androgen deprivation therapy. Targeting intracrine T and DHT synthesis should provide a mechanism to inhibit AR and
growth of castration-recurrent CaP.
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Introduction
Prostate cancer (CaP) is the most common non-skin cancer
diagnosed in American men. Despite earlier detection and
improved treatment, more than 33,000 deaths are anticipated in
2011 [1]. For decades, androgen deprivation therapy has been the
preferred treatment for locally advanced or metastatic CaP.
Androgen deprivation therapy is effective initially but remissions
are temporary. CaP that recurs responds poorly to most
treatments and almost all men succumb to the disease. A
molecular role for the androgen receptor (AR) in the transition
to castration-recurrent CaP is supported by the continuous
expression of AR [2–4] and androgen-regulated genes [5].
Many mechanisms contribute to AR transactivation despite
castrate levels of circulating testicular androgens (reviewed by
Feldman [6]). However, other studies including our own have
demonstrated that castration-recurrent CaP maintains tissue levels
of dihydrotestosterone (DHT) sufficient to activate AR [4,7–9].
Persistent tissue testosterone (T) and DHT during androgen
deprivation therapy may derive from adrenal androgens, such as
dehydroepiandrosterone (DHEA) and androstenedione [7], from
androstanediol through the backdoor pathway of DHT synthesis
[10,11] and/or de novo production from cholesterol [12]. In
castration-recurrent CaP, AR induces the androgen-dependent
expression of prostate-specific antigen and the transmembrane
protease, serine 2-v-ets erythroblastosis virus E26 oncogene
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that 70% of men with castration-recurrent CaP responded to
abiraterone acetate, a cytochrome P450 17a-hydroxylase/lyase
(CYP17A1) androgen biosynthesis inhibitor. The antitumor
activity of abiraterone acetate in clinical studies suggests that
inhibition of cytochrome P450 17a-hydroxylase/lyase (CYP17A1)
decreases ligand-activated AR signaling in castration-recurrent
CaP [14].
CWR-R1 cells used in the present study derive from the
castration-recurrent CWR22 xenograft [15], express the AR-
H874Y mutant [16] and proliferate in an androgen-deprived
environment. AR is comprised of an NH2-terminal transactivation
domain, a central DNA binding domain, and a carboxyl-terminal
ligand-binding domain (LBD) [17]. AR is full-length in CWR-R1
cells derived from the CWR22 human prostate cancer xenograft,
but is susceptible to proteolytic degradation during extraction to a
major ,80 kDa form [18]. AR transcriptional activity is mediated
by activation functions in the NH2-terminal and LBD. A unique
property of AR is that T or DHT induce an NH2- and carboxyl-
terminal (N/C) interaction [19] mediated by the NH2-terminal
FXXLF motif [20] that slows ligand dissociation and AR
degradation. A role of the NH2-terminal domain in gene
regulation [21–24] has also been reported for non-genomic AR
signaling [25].
In the present study, CWR-R1 cells were engineered using
lentivirus to overexpress the human AR with a deletion of NH2-
terminal activation residues 142–337 that results in a transcrip-
tionally inactive dominant negative AR. The human AR deletion
mutant ARD142–337 (ARDTR) binds ligand with high affinity but
is transcriptionally inactive in the absence or presence of androgen
[26]. The mechanism of dominant negative activity is hetero-
dimerization with endogenous AR to prevent transactivation of
target genes [27]. The results suggest that intratumoral T and
DHT synthesis induces dominant negative ARDTR inhibition AR
dependent CWR-R1 tumor growth. The androgen profile of
DTR-transduced CWR-R1 tumors in the absence of T support the
hypothesis that epithelial CaP cells produce AR ligands in a
murine model with low to undetectable adrenal androgen.
Results
ARDTR inhibits AR transactivation and CWR-R1 cell
proliferation
The effect of intracrine androgen synthesis and ARDTR
inhibition of endogenous AR and castration-recurrent CaP growth
was determined in CWR-R1 cells derived from the castration-
recurrent CWR22 human CaP xenograft. CWR-R1 cells
transduced with lentivirus expressing ARDTR or LacZ under
control of the CMV promoter exhibited high expression (Fig. 1).
The efficacy of ARDTR inhibition of AR transcriptional activity
was determined using MMTV-Luc transfected into lentivirus-
transduced CWR-R1 cells in the absence and presence of 0.1 nM
DHT because the prostate-specific antigen-luciferase reporter
gene is only weakly activated by endogenous AR [10,21,28].
Addition of 0.1 nM DHT LacZ-transduced CWR-R1 cells
increased luciferase activity by 3-fold (Fig. 2). Under the same
conditions, luciferase activity in ARDTR-transduced CWR-R1
cells was low with or without 0.1 nM DHT, an androgen
concentration that maximally stimulates androgen-regulated genes
in CWR-R1 cells [29]. The results demonstrate a dominant
negative effect of ARDTR on endogenous AR transactivation of
MMTV-luc in the absence and presence of DHT.
Inhibition of endogenous AR transactivation by ARDTR in the
absence of added DHT raised the possibility that endogenous AR
ligands induced ARDTR dimerization [30] and heterodimeriza-
tion between ARDTR and full-length endogenous AR [31]. Liquid
chromatography tandem mass spectrometry analysis demonstrated
3.3860.26 fmol T/million cells (n=4) and 1.8460.16 fmol
DHT/million cells (n=4) (Fig. 3). Since AR dimerization and
DNA binding are androgen-dependent [30], the results suggested
that ARDTR inhibitory activity can serve as a surrogate indicator
for intracellular active androgens.
The effect of ARDTR on androgen-dependent Nkx3.1 gene
expression [32] was assessed further to characterize the inhibitory
activity of ARDTR on AR signaling. Addition of DHT decreased
Nkx3.1 protein levels in ARDTR-transduced CWR-R1 cells
Figure 1. Overexpression of ARDTR or LacZ transgene in
lentiviral vector transduced CWR-R1 cells. Western blot analysis of
CWR-R1 protein lysates (20 mg) demonstrated that endogenous AR (Mr
110 kDa, lanes 1–2) is detected in both ARDTR and LacZ transduced
CWR-R1 cells using AR goat polyclonal antibody. LacZ (Mr 60.5 kDa, lane
1) expression is only observed in LacZ-transduced CWR-R1 cells using
LacZ rabbit polyclonal antibody and ARDTR (Mr 84 kDa, lane 2)
expression is detected using AR goat polyclonal antibody in ARDTR-
transduced CWR-R1 cells. Endogenous b-actin was detected using b-
actin AC-15 mouse monoclonal antibody (Mr 43 kDa, lanes 1 and 2) and
served as the loading control for both ARDTR and LacZ-transduced
CWR-R1 cells.
doi:10.1371/journal.pone.0030192.g001
Figure 2. Endogenous AR transcriptional activity in LacZ and
ARDTR lentiviral vector transduced CWR-R1 cells. CWR-R1 cells
were transiently transfected with the MMTV-luciferase reporter and
assayed for luciferase activity in the presence and absence of DHT. In
the presence of 0.1 nM DHT, CWR-R1 cells expressing the LacZ
transgene demonstrated an increase in MMTV-luciferase reporter
activity compared to control cells without DHT. Expression of ARDTR
reduced MMTV-luciferase reporter activity in the absence or presence of
0.1 nM DHT compared to LacZ-transduced control cells. Columns
represent mean luciferase activity in relative light units from 3
independent experiments; bars 6 standard deviation.
doi:10.1371/journal.pone.0030192.g002
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R1 control cells. Addition of DHT increased CWR-R1-LacZ cell
proliferation, but there was no increase in ARDTR-transduced
CWR-R1 cell proliferation. In the absence of added DHT, both
LacZ- and ARDTR-transduced CWR-R1 cells exhibited minimal
proliferation (Fig. 5).
ARDTR inhibits CWR-R1 tumor growth
LacZ or ARDTR-transduced cells were injected into nude mice
to generate CWR-R1 tumors to assess the impact of ARDTR on
tumor growth and endogenous AR signaling. Tumor growth rates
were altered by ARDTR expression. A rigorous mixed modeling
statistical analysis that considered individual tumor volume
trajectories demonstrated significant differences among the 4
groups (Fig. 6). The growth rate of LacZ controls differed with
exogenous T (p=0.04) (Fig. 6A and 6B), which indicated
Figure 3. Intracrine levels of DHT in CWR-R1 cells. DHT was measured in CWR-R1 cells grown without media supplements or exogenous T
using liquid chromatography tandem mass spectrometry. Representative chromatogram of DHT (left panel, DHT peak at 7.26 min) using 10 million
CWR-R1 cells (n=4). The mean concentration of DHT was 1.8460.16 fmol/million CWR-R1 cells. Control calibrator chromatogram of DHT standard
showing peak at 7.29 min (right panel).
doi:10.1371/journal.pone.0030192.g003
Figure 4. Expression level of androgen-regulated Nkx3.1
protein in CWR-R1 cells expressing LacZ or ARDTR transgene.
Immunoblot analysis of CWR-R1 cell protein lysates (20 mg) determined
Nkx3.1 protein expression using goat polyclonal antibody in the
presence or absence of 1.0 nM DHT. Nkx3.1 (Mr 35.5 kDa) protein was
increased in LacZ-transduced CWR-R1 cells with addition of DHT (lanes
1 and 2). ARDTR-transduced CWR-R1 cells exhibited decreased Nkx3.1
protein expression in the presence of DHT (lanes 3 and 4). Endogenous
b-actin (Mr 43 kDa) was used as loading control (lanes 1–4).
doi:10.1371/journal.pone.0030192.g004
Figure 5. ARDTR-transduced CWR-R1 cells demonstrate de-
creased proliferation in the presence of DHT. Cell proliferation
was determined using XTT
R assay and monitoring absorbance at 490/
690 nm in triplicate from day 1 to day 8 (mean 6 standard deviation).
CWR-R1 cells expressing ARDTR (solid diamond and black line) or LacZ
(solid square and grey line) transgene in the absence of 0.1 nM DHT
showed similar growth curves (upper panel). In the presence of 0.1 nM
DHT, ARDTR-transduced CWR-R1 cell growth decreased compared to
LacZ-transduced control CWR-R1 cells (lower panel).
doi:10.1371/journal.pone.0030192.g005
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mental groups. ARDTR reduced tumor growth rates compared
to controls, an effect that was similar without (p=0.01) or with
exogenous T (p=0.0004) (Fig. 6C and 6D). Results were
similar when tumor growth was assessed using two additional
parameters. LacZ and LacZ+T controls differed by slope
(p=0.01) and doubling time (p=0.02), which confirmed the
need for different controls for each ARDTR experimental group.
T supplements to optimize ARDTR function decreased tumor
growth compared to controls by slope (p=0.004) and doubling
time (p=0.0007). Without T supplements, tumor growth slope
(p=0.07) and doubling time (p=0.37) were similar. Inspection
of the individual tumor trajectories and actual tumor volumes
suggested that the effect of ARDTR was a combination of
slowing the rate of growth and delaying the onset of tumor
growth, and that this effect occurred more often when
exogenous T is provided to enhance the effect of ARDTR
(Fig. 6E).
ARDTR-induced changes in tumor growth rate also affected
the time of euthanasia determined by tumor size exceeding
1.5 cm
3 (Fig. 7,K a p l a n - M e i e rp l o t ;Table 1,L o gr a n k
analysis, p=0.009). 95% confidence intervals for the mean
time to euthanasia in days and the range for each group were
LacZ (71, 68–84 days), LacZ+T (63, 57–68 days), ARDTR (75,
68–89 days), and ARDTR+T (89, 68–105 days). ARDTR
increased the time to host median euthanasia by 36% in the
presence of exogenous T, but had little effect without
exogenous T. Median time to euthanasia increased by 5% in
the absence of exogenous T, a difference that was not
statistically significant.
Negative selection of ARDTR in CWR-R1 tumors
The similar time to euthanasia based on tumor size between
CWR-R1-ARDTR and LacZ mice in the absence of androgen
suggested that ARDTR cells select against ARDTR expression. To
Figure 6. Individual mouse CWR-R1 tumor volume (cm
3) trajectories and predicted mean tumor volumes from each cohort. Tumors
were measured using digital calipers and volumes calculated from day 14 to day 160 after CWR-R1 cell inoculation. Tumor volumes, LacZ (A, n=22),
LacZ+T (B, n=21), ARDTR (C, n=21) or ARDTR+T (D, n=21), are shown from day 21 when growth began through day 96 beyond which only 1 mouse
in each group remained. Mixed modeling statistical analysis showed a statistically significant difference among the 4 groups. ARDTR-transduced
CWR-R1 tumor growth rates were reduced compared to LacZ controls in the absence (p=0.01, panel A vs. C) or presence (p=0.0004, panel C vs. D) of
T. (E) Predicted mean CWR-R1 tumor volumes (cm
3) were plotted against time of first tumor harvest for the LacZ+T (open squares), LacZ (open
diamonds), ARDTR+T (solid circles) and ARDTR (open circles) groups. ARDTR-expressing CWR-R1 tumors (circles) exhibit decreased growth rates
compared to LacZ-transduced CWR-R1 control cells.
doi:10.1371/journal.pone.0030192.g006
Figure 7. Kaplan-Meier plots from each cohort. Day of euthanasia
was based on 1.5 cm
3 tumor size for mice in the LacZ+T (dashed line,
n=21), LacZ (dotted line, n=22), ARDTR (solid line, n=21) or ARDTR+T
(broken line, n=21) groups. The median survival time differed in groups
that received exogenous T (broken line vs. dashed line, p=0.008) but
not in groups without T (solid line vs. dotted line, p=0.34).
doi:10.1371/journal.pone.0030192.g007
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protein expression were determined in CWR-R1 tumors.
ARDTR or LacZ vector copy numbers and protein expression
were determined in transduced CWR-R1 cells prior to
inoculation and at the time of tumor harvest. ARDTR or LacZ
vector copy number per cell measured in CWR-R1-transduced
cells prior to inoculation based on PCR amplification of the
Woodchuck hepatitis virus post-transcriptional regulator ele-
ment was 5.46 and 4.53, respectively. Mean (6 standard
deviation) vector copy number per cell for ARDTR and LacZ-
transduced CWR-R1 tumors at the time of harvest was
0.4960.58 for ARDTR+T and 2.5861.68 for ARDTR
(p=0.001), and 3.1061.77 for LacZ+T and 3.4861.45 for
LacZ (p=0.4) (Fig. 8).
To characterize further the effect of ARDTR on vector copy
number, ratios of vector copy number per cell in CWR-R1 cells
were calculated at the time of tumor harvest and at the time prior
to CWR-R1 cell inoculation for ARDTR and LacZ tumors in the
presence and absence of T. Statistical analysis of median vector
copy number per tumor cell ratios for ARDTR and LacZ
expressing vectors showed that the ARDTR expression vector
cassette was selected against (p=0.006, Fig. 9A). A similar
statistical result was obtained in the median vector copy number
per tumor cell ratio for ARDTR and LacZ expressing vectors in
the presence of T (p,0.0001, Fig. 9B). Overall, ARDTR-
transduced CWR-R1 cells in the presence or absence of exogenous
T selected against the ARDTR vector compared to LacZ vector
controls.
The altered median ARDTR and LacZ vector copy number per
tumor cell ratios suggested decreased ARDTR protein expression
compared to LacZ controls. Harvested CWR-R1 tumors with
sufficient amounts of tissue (79 tumors) for analysis of endogenous
AR and expressed ARDTR or LacZ protein were analyzed on
immunoblots. Expression of endogenous AR and ARDTR protein
was demonstrated in pTK989-ARDTR transduced CWR-R1 cells
prior to subcutaneous inoculation. ARDTR-transduced CWR-R1
tumors in the presence of T (Fig. 10A), expressed endogenous AR
in all 22 CWR-R1-ARDTR+T tumors, although AR protein was
low to undetectable in 3 samples (samples 21–23). In contrast,
ARDTR protein was negligible or absent in all CWR-R1-ARDTR
tumors in the presence of T supplements.
In the absence of supplemental T, AR protein persisted in 10 of
15 CWR-R1-ARDTR tumors (tumor numbers 28, 29, 31, 32, 34,
35, 38, 39, 43 and 44), and endogenous AR was not detected in 5
tumors that also did not express ARDTR (samples 24–27 and 33)
(Fig. 10B). CWR-R1-ARDTR tumors 32 and 35 without the T
supplement expressed AR but not ARDTR. ARDTR was co-
expressed in 8 CWR-R1 tumors (tumor numbers 28, 29, 31, 34,
38, 39, 43 and 44).
In contrast, LacZ protein was expressed in all tumors except
tumor 72 in the absence and presence of T (Fig. 10C). Empty
vector control CWR-R1 tumors with T (samples 92 and 93) and
without T (samples 94 and 95) and 293T cells did not express
LacZ or ARDTR protein. The consistent expression of LacZ
protein corresponded with vector copy number calculated in
LacZ-transduced tumors.
The results suggest negative selection of ARDTR is not limited
to CWR-R1-ARDTR tumors propagated in mice with supple-
mental T. In ARDTR-transduced tumors without supplemental T,
ARDTR selection was less possibly due to low serum T and/or
altered intracrine T biosynthesis.
Intracrine synthesis of active androgens in castration-
recurrent CaP
The absence of CYP17A1 in mouse adrenals [33] provides a
model to test whether castration-recurrent CaP produces intra-
crine androgens. Generation of the CWR-R1-ARDTR tumors
provided an opportunity to investigate an effect of AR signaling on
intracrine active androgen biosynthesis. The similar CWR-R1-
ARDTR tumor growth, tumor doubling times and slopes with and
without T, and measurements of DHT in CWR-R1 cells suggested
that CWR-R1 tumors produced active androgens in the absence
of circulating T.
To identify possible differences in androgen profiles between
CWR-R1-ARDTR and LacZ tumors, T, DHT, androstenedione
and androsterone were measured using liquid chromatography
tandem mass spectrometry. Tissue levels of 0.32 nM DHT
(p=0.59) and 0.05 nM androsterone (p=0.23) measured at the
time of tumor harvest were similar in ARDTR and LacZ-
transduced tumors (Table 2) and sufficient to activate endoge-
nous AR and ARDTR (see in vitro results; Fig. 2). Furthermore,
3.25 nM T in LacZ tumors was similar to T levels in castration-
recurrent CaP [4,9] that was sufficient to activate endogenous
AR-H874Y [29]. However, in CWR-R1-ARDTR tumors, T
levels were ,4-fold less than LacZ tumors, which suggested
alteration in T biosynthesis by the dominant negative AR.
Decreased T biosynthesis in ARDTR-transduced CWR-R1
tumors correlated with the accumulation of ,1 nM androstene-
dione, an androgen precursor to T. In contrast, CWR-R1-LacZ
tumors contained 1.05 nM androstenedione. Quantitation of 5a-
reduced and unsaturated androgen precursors in ARDTR and
LacZ-transduced CWR-R1 tumors suggested intracrine andro-
gen biosynthesis contributed to AR-dependent castration-recur-
rent CaP growth.
Table 1. Log-Rank Test p-values in Order of Stepdown Pair-
Wise Comparisons of Overall Survival Family-Wise Error Rate
(FWR) Controlled p-values.
Comparison log-rank test p-value
LacZ+T LacZ 0.03
LacZ+TA R DTR+T 0.008
LacZ ARDTR 0.34
ARDTR ARDTR+T 0.59
Overall 0.009
doi:10.1371/journal.pone.0030192.t001
Figure 8. ARDTR and LacZ mean vector copy number/cell in
harvested CWR-R1 tumors with and without T. Vector copy
number per cell was determined using quantitative PCR of the
Woodchuck hepatitis virus post-transcriptional regulator element. The
mean vector copy number per cell is 0.4960.58 for ARDTR+T, 2.5861.68
for ARDTR, 3.1061.77 for LacZ+T and 3.4861.45 for LacZ tumors. A
statistically significant decrease in vector copy number per cell was
observed for ARDTR+Tv sA R DTR tumors (p=0.001) but not LacZ+T vs.
LacZ (p=0.4) tumors.
doi:10.1371/journal.pone.0030192.g008
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Studies in this report were based on the premise that a
dominant negative form of AR with a deletion of the NH2-
terminal transactivation domain requires androgen for dimeriza-
tion [30] and inhibition of transcriptional activity of full-length AR
[27]. We have shown that stable expression of dominant negative
ARDTR inhibits endogenous AR-H874Y transcriptional activity
and slows or delays CWR-R1 tumor growth in the absence and
presence of supplemental T. Dominant negative ARDTR activity
was also indicated by the decrease in Nkx3.1 protein and luciferase
reporter activity in the presence of DHT.
Results from the study have revealed two additional important
findings. First, there was essentially 100% negative selection
against the dominant negative form of AR during castration-
recurrent CWR-R1 tumor growth in the presence of supplemental
T. This contrasted nearly 100% retention of the LacZ control
gene. Both dominant negative ARDTR and LacZ were integrated
into the genome using lentivirus expression and cell selection prior
to cell inoculation and tumor growth. Second, approximately 50%
Figure 9. Median vector copy number/cell ratio of harvested CWR-R1 tumor cells versus CWR-R1 cells prior to inoculation. The ratios
for (A) ARDTR and LacZ, and (B) ARDTR+T and LacZ+T were calculated using the vector copy number measured at time of tumor harvest versus the
vector copy number measured prior to inoculation. Individual tumor vector copy number per cell ratio from each cohort is represented using open
circles. The median vector copy number ratio (solid circle) was determined in ARDTR (0.43), LacZ (0.64), ARDTR+T (0.05), and LacZ+T (0.6) tumors. The
ARDTR transgene was selected against in the absence (p=0.006) and presence (p,0.0001) of exogenous T compared to LacZ controls.
doi:10.1371/journal.pone.0030192.g009
Figure 10. ARDTR and LacZ protein expression in CWR-R1 tumors with or without exogenous T. Western blot analysis was performed
using protein lysates isolated from CWR-R1 tumors collected at the time of tumor harvest. The CWR-R1 tumor expression of endogenous AR (Mr
110 kDa), and transduced ARDTR (ARD142–337, Mr 84 kDa) and LacZ (Mr 60.5 kDa) protein were evaluated. (A) Immunoblots of AR and ARDTR in the
presence of T (tumor numbers 2–23) or (B) absence of T (tumor numbers 24–29, 31–35, 38, 39, 43 and 44). (C) Immunoblots of LacZ (Mr 60.5 kDa)
protein with T (tumor numbers 47–68) or without T (tumor numbers 69–91) and in empty vector controls (tumor numbers 92–95). LacZ was
expressed in all but one of 42 CWR-R1 tumors. LacZ protein expressed in pTK1027 transduced CWR-R1 cells prior to subcutaneous inoculation in mice
was used for control. HEK-293T cells were used as negative controls and the loading control for LacZ immunoblots was glucose 6-phosphate
dehydrogenase (GADPH, Mr 36 kDa).
doi:10.1371/journal.pone.0030192.g010
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ARDTR tumors propagated in the absence of supplemental T.
These results, together with mass spectrometry measurements of T
and DHT in cultured CWR-R1 cells, provide evidence for
intracrine synthesis of active androgens needed for AR signaling in
CaP. Selective loss of a dominant negative AR demonstrates the
genetic versatility of castration-recurrent CaP cells to maximize
AR signaling.
Intracrine synthesis of androgen in castration-recurrent
CaP
Inhibition of luciferase activity in CWR-R1 cells by dominant
negative ARDTR in the absence of exogenous T suggested
intracellular synthesis of T. This was supported by mass
spectrometry measurements of T and DHT in CWR-R1 cells.
Our findings are in agreement with previous evidence that
androgen-starved LNCaP cells synthesize androgens from
14C-
acetate labeled cholesterol [34]. CaP cells alter cholesterol
metabolism and processing to support androgen biosynthesis
[35]. Intracrine biosynthesis of androstenedione, DHEA and T
was also demonstrated in CWR-R1 and PC-3 cells, and
implicated CYP17A1 activity in AR positive and negative CaP
cells [36]. In clinical specimens, cholesterol and androgen
biosynthetic enzymes were up-regulated in castration-recurrent
CaP [12,37,38].
In the CWR-R1-LacZ tumors, intratumoral T and DHT levels
were sufficient to activate AR-H874Y and promote tumor growth.
Intratumoral DHT levels in ARDTR and LacZ-transduced
tumors were similar. However, in ARDTR-transduced CWR-R1
xenograft tumors, T levels were lower and androstenedione levels
were greater than CWR-R1-LacZ tumors. Lower T levels in the
CWR-R1-ARDTR tumor suggested that dominant negative
ARDTR selected against cells expressing aldo-keto reductase
1C3, an enzyme that reduces androstenedione to T in castration-
recurrent CaP, or increased the oxidation of T to androstenedione
by NAD
+ dependent 17b-hydroxysteroid dehydrogenase-10
activity [39]. Decreased conversion of androstenedione to T
would shift the intracellular ligand profile toward activation of
mutant AR-H874Y from wild-type LBD AR in ARDTR.
Intracrine metabolism of cholesterol to active androgens could
explain the initial sensitivity of castration-recurrent CaP to
treatment with abiraterone acetate [14].
AR-H874Y endogenous to CWR-R1 cells retains high affinity
Ta n dD H Tb i n d i n gs i m i l a rt ow i l d - t y p eA R .H o w e v e r ,t h e
H874Y mutation stabilizes the LBD core structure so that T is
as effective as DHT in promoting transcriptional activity [29].
The structure stabilizing effects of H874Y are sufficient to
overcome the detrimental effectso fl o s so ff u n c t i o nm u t a t i o n s
that cause androgen insensitivity [40]. The equivalent potency
of T and DHT with AR-H874Y suggests that intracrine
synthesis of T would promote LacZ-transduced CWR-R1
tumor growth. Intracellular conversion of androstenedione to
T could have a substantial transcriptional effect on AR-H874Y
relative to wild-type AR [29]. Increased expression of p160
steroid receptor coactivators in castration-recurrent CaP [41,42]
contributed to the hypersensitization.
T:DHT ratios in LacZ- and ARDTR-transduced CWR-R1
tumors were similar to those in castration-recurrent CaP [4,9,43].
Previous studies using clinical specimens demonstrated decreased
5a-reductase-2 isozyme mRNA [44] and protein [45] expression
in castration-recurrent CaP that was partially due to loss of
secreted stromal cell factor signaling [44,46]. CWR-R1 tumors
also may have decreased 5a-reductase-2 activity. The similar
DHT levels in LacZ and ARDTR tumors indicate that DHT
biosynthesis depends on androstenedione rather than T, since
androstenedione is a better substrate for 5a-reductase-1 than T
[47]. The shift toward conversion of androstenedione to
androstanedione [45] by 5a-reductase-1 and further metabolism
to DHT by membrane bound NADPH dependent 17b-hydroxy-
steroid dehydrogenase-15 [48] may explain why men with
castration-recurrent CaP and high baseline androstenedione levels
survived longer when treated with ketoconazole [49]. DHT levels
remain similar even though the T:androstenedione ratios in LacZ
and ARDTR tumors were inversed. The low and similar DHT
levels (,10
211) measured in LacZ and ARDTR-transduced
CWR-R1 tumors may be the optimum intratumoral concentration
for CWR-R1 cell proliferation [42] and AR-H874Y coordinated
DNA replication licensing [50].
Negative selection to enhance AR activity
The growth inhibitory effects of ARDTR were complicated by
the fact that the ARDTR transgene was negatively selected against
during CWR-R1 tumor growth most efficiently in the presence of
supplemental T. Expression of the ARDTR transgene was lost in
all of the 22 ARDTR+T tumors by the time of harvest, while the
ARDTR transgene was retained in ,50% of tumors in the
absence of supplemental T. The mean tumor volume was larger
than ARDTR+T tumors, which may be associated with a partial
switch from T to androstenedione biosynthesis by these tumors.
Although the timing of negative selection against the ARDTR
transgene was not rigorously tested, preliminary studies suggested
loss of the transgene occurred approximately 10 days after tumor
cell inoculation on day 23.
Negative selection of the ARDTR transgene was supported by
the decreased genome vector copy number in both ARDTR and
LacZ-transduced CWR-R1 tumors in the absence or presence of
exogenous T. Loss of transgene expression has been shown to
occur 10 to 15 days after lentiviral transduced embryonic
carcinoma cells [51]. The delay in ARDTR+T tumor growth
supported selection against the transgene after 10 days in the
CWR-R1 model. It could be argued that loss of the transgene
resulted from vector escape from variegation and/or extinction
events. On the other hand, random gene or chromosomal deletion
and transgene silencing [51] were not supported, as there was
nearly complete retention of the control LacZ transgene in the
CWR-R1 tumors.
Table 2. Mean androgen levels (nM, 6 SEM) measured in LacZ (n=8) and dominant-negative ARDTR (n=11) CWR-R1 androgen-
independent tumors without exogenous T pellets.
Androstenedione Testosterone Dihydrotestosterone Androsterone
LacZ 1.0560.18 3.2560.37 0.2860.17 0.0760.02
ARDTR 13.664.9 0.7960.33 0.3260.11 0.0560.02
doi:10.1371/journal.pone.0030192.t002
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as the parental CWR22 CaP xenografts, contain replication
competent retroviruses identical to the xenotropic murine
leukemia related virus (XMRV) found in human CaP cells
[52,53]. XMRV evolved by recombination between two endog-
enous retroviruses in nude mice carrying the CWR22 xenografts
[52,53]. XMRV proviruses were not detected in samples obtained
from early CWR22 tumor passages, which is consistent with newer
reports that XMRV is not involved in the development of CaP in
humans. The data presented herein does not exclude the unlikely
possibility that XMRV infection contributes to castration-
independence of CWR-R1 cells (derived from CWR22) [53];
Paprotka et al. found this scenario most unlikely. The experiments
were well controlled and XMRV infection was present in
experimental and control animals. Overall, the results presented
here demonstrate inhibition of the CWR-R1 tumor growth by
dominant negative inhibition of AR signaling, and indicate the
central role of tumor-derived androgens in the development of
castration-resistant CaP. The decrease and delay in castration-
recurrent tumor growth, coupled with a 36% extension of survival
in the presence of T, supported the importance of inhibition of AR
expression/activity as a clinical target [54,55].
Materials and Methods
Generation of ARDTR and LacZ transduced CWR-R1 cells
The coding region of pCMV-hARD142–337 with wild-type
LBD and FXXLF motif binding motif [20] was subcloned into the
BamHI site of SK+ plasmid (Stratagene, La Jolla, CA). The
plasmid was digested with XhoI/SpeI and the fragment was
subcloned into the XhoI/XbaI site of HIV-1 based vector
pTK642 upstream of the IRES-GFP-BSD cassette. The resulting
vector pTK989 expressed ARDTR under control of the human
cytomegalovirus promoter (Fig. 11). LacZ expression vector
pTK1027 was generated by ligation of the SmaI/XhoI fragment
that contains LacZ cDNA pTK1022 into pTK642 digested with
HpaI/XhoI. All plasmid sequences were confirmed using direct
sequencing.
HIV-1 based vectors were generated using a transient 3-plasmid
transfection method. The standard calcium phosphate protocol was
used as described [56]. Briefly, vector constructs (15 mg), vesicular
stomatitis virus glycoprotein envelope expression cassette (5 mg) and
DNRF packaging cassettes (10 mg) were transfected into 293T cells
(ATCC #11268). Lentiviral particles were collected 60 h after
transfection from filtered conditioned medium. Lentivirus stocks
were aliquoted and stored at 280uC. Virus titers were determined
by scoring green fluorescent protein expression following serial
dilutions on 293T cells and/or by using the p24 ELISA assay
(PerkinElmer Life Sciences, Inc., Waltham, MA, catalog
#NEK050). CWR-R1 cells (passage 21) propagated as described
[15] were tranduced with lentivirus-ARDTR or lentivirus-LacZ at
multiplicity of infection 5 and selected using blasticidin (Invitrogen,
Carlsbad CA, 20 mg/mL).
Lentivirus transduced CWR-R1 endogenous AR
transactivation and cell proliferation
Blasticidin-selected ARDTR or LacZ CWR-R1 cells (10
6 cells/
6 cm dish) were transfected with 0.5 mg mouse mammary tumor
virus luciferase (MMTV-Luc) reporter vector using Effectene
reagent (Qiagen, Valencia, CA). After transfection, cells were
placed in serum-free, phenol red-free medium in the absence or
presence of 0.1 nM DHT. Twenty-four h later, medium with or
without DHT was exchanged. Luciferase assays were performed
the next day using the Luciferase Assay System (Promega,
Madison, WI). ARDTR or LacZ-transduced CWR-R1 cell
proliferation assays were performed using the XTT
R assay kit
(Roche, Indianapolis, IN, catalog #11465015) in the presence and
absence of 0.1 nM DHT.
CWR-R1 cell and tumor immunoblot analysis
AR, ARDTR, LacZ and Nkx3.1 homeobox protein immuno-
blot analyses were performed as described [15] using CWR-R1
cells treated with 1 nM DHT or CWR-R1 tumor specimens
stored at 280uC. Protein lysates (20 mg) prepared from CWR-R1
cells or pulverized CWR-R1 tumor specimens were separated
using 4–8% acrylamide gradient gels containing SDS and
electroblotted to nitrocellulose membranes (NitrobindH, Osmo-
nics, Inc., Minnentonka, MN). Antihuman AR goat polyclonal
antibody (Abcam, Cambridge, MA, catalog #ab19066, 1:1000)
targeted AR N-terminal amino acids 2–16. Rabbit polyclonal
LacZ antibody (Millipore, Billerica, MA, catalog #AB1211) and
rabbit polyclonal GADPH (Santa Cruz Biotechnology, Santa
Cruz, CA, catalogue # sc-25778) were used at 1:1000 dilution.
Nkx3.1 goat polyclonal antibody (Santa Cruz Biotechnology, Inc,
Santa Cruz, CA, catalog #sc-15021) and b-actin AC-15 mouse
monoclonal antibody (Abcam, Inc., catalog #ab6276) were used
at 1:1000 and 1:5000 dilutions, respectively. Secondary rabbit-
antigoat, goat-antirabbit or anti-mouse IgG antibodies conjugated
to horseradish peroxidase were used at 1:10,000 dilution (Pierce,
Rockford, IL). Specific signals were detected using enhanced
chemiluminescence (Amersham Pharmacia Biotech, Piscataway,
NJ).
CWR-R1 tumor studies
Mice were maintained and experimental procedures performed
in accordance with the National Institute of Health, the University
of North Carolina School of Medicine Institutional Animal Care
and Use Committee and the Institutional Biosafety Committee.
Male athymic nude mice 4 to 5 weeks old were purchased from
Harlan Sprague-Dawley, Inc. (Indianapolis, IN) and housed
individually in the Division of Laboratory Medicine facility at
Figure 11. Dominant-negative androgen receptor (ARDTR, pTK989) and b-galactosidase (LacZ, pTK1027) lentiviral expression
vector diagrams. The residual HIV-1 content of both vectors includes the long terminal repeat (LTR) regions, packaging signal of HIV-1 (y) and the
polypurine tract (cPPT). The 59 CMV promoter and polyadenylation signal in the 59 LTR direct high level expression of transfer vector genome. The
internal expression cassette consists of CMV promoter, respective transgene coding sequences of the dominant-negative human androgen receptor
(DTR) or b-galactosidase (LacZ), the internal ribosome entry site (IRES) to express green fluorescence protein fused to blasticidin resistance gene (GFP-
BSD
R) and the Woodchuck hepatitis virus post-transcriptional regulatory element. The 39 LTR contains U3 deleted self-inactivating sequence (DU3).
doi:10.1371/journal.pone.0030192.g011
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was identified using a numbered ear tag. Two days after
castration, mice were divided into two groups of 45 mice each.
One T pellet (12.5 mg, 90-day release) was implanted subcutane-
ously in each of 22 mice from each group to normalize circulating
levels to ,4 ng/mL T (Innovative Research, Sarasota, FL). Mice
were inoculated subcutaneously on one flank with 1.25610
6
CWR-R1 blasticidin-selected cells suspended in Matrigel (1:1
mixture, BD Biosciences, Bedford, MA). Matrigel was used to
promote xenograft formation in the castrate microenvironment of
the inoculation site [57]. Mice received cells transduced with
lentivirus-ARDTR or lentivirus-LacZ. The tumor growth sup-
pressing or promoting activity of host innate immune system was
accounted for by comparing ARDTR to control lentivirus-LacZ
groups. Tumor volume was measured at least 3 times per week
using digital calipers and volume calculated using the equation
L16(L2)
260.523. Mice were euthanized and tumors excised when
tumor volume reached 1.5 cm
3. Tumors were cut into ,0.1 cm
3
pieces with 1/3 frozen in liquid nitrogen and stored at 280uC, 1/3
immersed in RNAlater (Ambion, Austin, TX) for 24 h and stored
at 280uC, and 1/3 fixed in 10% formalin-buffered saline for 24 h,
washed in phosphate buffered saline and embedded in paraffin.
Quantitative PCR
Quantitative PCR of the Woodchuck hepatitis virus post-
transcriptional regulatory element was performed to assess
ARDTR and LacZ transgene integration and retention using the
7500 Real Time PCR System and SDSv1.x Software (Applied
Biosystems, Foster City, CA). DNA was isolated from RNAlater
treated frozen tumor samples and prepared for real-time PCR as
described [58]. In brief, tumor DNA were digested with restriction
enzyme DpnI to degrade plasmid/vector DNA that remained
after transfection. Genomic DNA (10 ng) was normalized using
human b-globin gene (2 copies/diploid cell). DNA (1 ng) was
calculated equal to 151.5 copies for 1 copy/diploid cell, or 303
copies for 2 copies/diploid cell. An equal b-globin equivalent was
used to amplify viral DNA. DNA isolated from FLP9 cells that
contained a single copy of provirus per diploid cell was used as a
standard [59]. The FLP9 cell line was generated by the Flip-In
System (Invitrogen) employing Flip-mediated recombination to
introduce a single lentiviral vector genome into HEK293 genome
containing a single FRT site. Primers for b-globin gene were
forward primer 59-CAGAGCCATCTATTGCTTAC -39 and
reverse primer 59-GCCTCACCACCAACTTCATC-39. Lentivi-
rus specific primers to amplify the WRPE sequence were forward
primer 59-ACGTCCTTCTGCTACGTCC-39 and reverse primer
59-AAAGGGAGATCCGACCGACTCGTC-39. The quantita-
tive PCR reaction contained 16Master mix (Promega, Madison,
WI), 0.086 SYBRH Green I (Cambrex Bio Science, Rockland,
ME), 300 nM forward primer, 300 nM reverse primer and
template in a total volume of 15 mL. Quantitative-PCR conditions
were 95uC for 5 min; 40 cycles at 95uC for 30 sec; annealing at
55uC for 30 sec; and extension at 72uC for 30 sec. A minus
template incubation was used as control. An aliquot (10 mL) of
each PCR reaction was subjected to gel electrophoresis. PCR
products were visualized using ethidium bromide staining. Each
experiment was performed 3 times.
Androgen measurements in CWR-R1 tumors
Tumor samples stored at 280uC were pulverized using liquid
nitrogen. Tissue was transferred into high pressure liquid
chromatography grade water (50 mg/mL) containing deuterated
internal standard, 5a-androstan-17b-ol-3-one-16,16,17-d3 (1.0 ng,
CDN isotopes, Pointe-Claire, Quebec, Canada). Samples were
homogenized and extracted 3 times with 1 mL chloroform:acetone
(9:1). Organic extracts were combined and dried. Androgens were
purified and concentrated using solid phase C18 extraction
cartridges (Varian, Palo Alto, CA). Liquid chromatography tandem
mass spectrometry was performed as described [9] using the AB
SCIEX Triple Quad
TM 3000 system (Applied Biosystems, Foster
City, CA) with modification. Steroids were eluted using a linear
gradient of 65% to 80% mobile phase A (0.4 mM ammonium
formate) for 2.25 min and mobile phase B (0.4 mM ammonium
formate in methanol) followed by isocratic elution at 95% mobile
phase A for 13 min at flow rate 175 mL/min at 60uC. A
Phenomenex Luna C18 column (3.0 mm, 15062 mm) was used
to separate T, DHT, androstenedione and androsterone. The
parent–product positive ion pairs monitored (mass to charge ratio)
were 289.2 to 97.0 for T, 291.2 to 255.2 for DHT, 294.2 to 258.2
for5a-androstan-17b-ol-3-one-16,16,17-d3 internal standard,287.2
to 97 for androstenedione and 291.2 to 255.2 for androsterone.
Statistical Methods
Tumor volumes were measured serially and analyzed using
random coefficient modeling beginning on day 14 after cell
inoculation until the tumor volume exceeded 1.5 cm
3 when the
mice were euthanized (the longest was day 204). The primary
interest of this analysis was to investigate the pair-wise difference in
growth rates of CWR-R1-ARDTR, ARDTR+T, LacZ and
LacZ+T tumors. This approach was chosen a priori that used a
step-down approach to control the family-wise error rate for
statistical comparisons of interest. The nonparametric Wilcoxon
rank-sum test (with Van der Waerden normal scores) was used for
each of the pair-wise 2-group comparisons, when summary
measures of slopes and doubling times were compared. The
Kruskal-Wallis test (with Van der Waerden normal scores) was
used when more than 2 groups were compared. These
comparisons yielded essentially equivalent results to parametric
random coefficient modeling. The Kaplan-Meier method was
used to estimate the time to euthanasia function for each of the 4
groups. The log-rank test was used to test for differences among
survival curves. Statistical analyzes were performed using SAS
statistical software, version 9.2 from the SAS Institute, Inc., Cary,
NC.
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